We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Teams Place 15 and 28 out of 120 Teams The West DragonPhyre and DragonPhlame teams placed 15th and 28th, respectively, out of the 120 teams competing at the 11th Annual Philadelphia Dragonboat Festival on October 6, 2012.
DragonPhyre paddled to first place in both the qualifying and semi-final rounds, and finished 4th in the final round of the B Division race with a time of 2:24.98.
DragonPhlame rowed to third in the qualifying race, fourth in the semi-final and 5th place in the C Division finals with a time of 2:36.97.
More than 40 West employees, family members and friends participated in this year’s race. Funds were raised through a variety of activities, including raffles, Puppy Bingo and t-shirt sales. Thanks to all those who donated to this amazing campaign!
West's contract manufacturing team has once again reached a record level of support for Temple Street Children’s Hospital and recently presented a check for €18,000 that was raised by employees in 2015.
The definitions of <em>personalized medicine</em> vary. However, all of them indicate that the once popular therapy approach of “<em>one drug fits all</em>” is outdated. The Council of the European Union defines personalized medicine as <em>“[p]roviding the right treatment to the right patient, at the right dose at the right time.”</em><sup>[1]</sup>.
Bart Burgess, Director, Business Development, Self-Injection Systems at West, and Peter Krulevitch, Ph.D., Engineering Director, Packaging, Devices & Delivery at Janssen Pharmaceutical Companies of Johnson & Johnson will present “A New Self-Injection Technology and Unique Partnership” at the Drug Delivery Partnership Conference. The conference will be held February 6-8, 2013, at the Hilton San Diego Bayfront, San Diego, CA.
Beginning in 1998, when an increase in the incidence of pure red cell aplasia (PRCA) was observed in patients with chronic renal failure and associated with the subcutaneous use of Eprex<sup>®</sup> (epoetin alpha), the U.S Food and Drug Administration (FDA) and European regulatory agencies have paid special attention to leachables in drug products especially resulting from uncoated primary elastomer components.
To improve the consistent evaluation of the quality and efficacy of generic drugs for injections, National Medical Products Administration of China（NMPA）published the guidance “Technical Requirement for Quality and Efficacy Consistency Evaluation on Chemical Generic Injections” (21 October 2020), which indicates the beginning of injection consistency evaluation. This guidance clarifies the specific technical requirements on reference-listed drugs, prescription technology, quality control of bulk drugs and excipient packaging, quality studies and control, stability studies, etc. <br />Container Closure Integrity (CCI) is one of the key factors for the quality and safety of the entire product lifecycle of pharmaceuticals. To better address this topic, NMPA issued “Technical Guide for Research on Package Integrity of Chemical Injections (Trial)” on 21 October 2020. And 4 years later, “9650 Guidelines for Research on Pharmaceutical Package Integrity” is published as Chinese Pharmacopoeia (ChP) 2025 chapter on 19 Feb 2024. This new publicity helps to guide the implementation of CCI of pharmaceutical packaging materials and provides effective ways to comprehensively assure the quality of drugs.
English
Chinese
